Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
Autolus Therapeutics Q1 Earnings Call Highlights
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Stock Traders Purchase Large Volume of Autolus Therapeutics Call Options (NASDAQ:AUTL)
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.33 Average Target Price from Brokerages
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New Strong Sell Stocks for January 30th
New Strong Sell Stocks for January 22nd
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform
Perpetual Ltd Has $784,000 Position in Autolus Therapeutics PLC Sponsored ADR $AUTL
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
Cetera Investment Advisers Has $1.41 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable
Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market